NCT03985982 - Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII) | Biotech Hunter

Enrollment

410

Participants

Timeline

Start Date

April 29, 2019

Primary Completion Date

December 4, 2019

Study Completion Date

December 22, 2020

Conditions

Glabellar Frown Lines

Interventions

DRUG

Botulinum Toxin A

Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area

DRUG

Placebo

injection, sodium chloride 0.9 % divided in five 0.1 mL i.m injections into the glabellar area

DRUG

Botulinum Toxin A

Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area in up to 3 treatment cycles

Trial Locations (1)

Tennessee Clinical Research Center, Nashville